Pomalidomide

Pomalidomide
Clinical data
Trade names	Pomalyst, Imnovid
AHFS/Drugs.com	Monograph
MedlinePlus	a613030
License data	EU EMA: by INN; US DailyMed: Pomalidomide;
Pregnancy; category	AU: X (High risk);
Routes of; administration	By mouth
ATC code	L04AX06 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); BR: Class C3 (Immunosuppressive drugs); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	73% (at least)
Protein binding	12–44%
Metabolism	Liver (mostly CYP1A2- and CYP3A4-mediated; some minor contributions by CYP2C19 and CYP2D6)
Elimination half-life	7.5 hours
Excretion	Urine (73%), faeces (15%)
Identifiers
	IUPAC name 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione;
CAS Number	19171-19-8 ;
PubChem CID	134780;
IUPHAR/BPS	7348;
DrugBank	DB08910 ;
ChemSpider	118785 ;
UNII	D2UX06XLB5;
KEGG	D08976 ;
ChEMBL	ChEMBL43452 ;
CompTox Dashboard (EPA)	DTXSID40893458 ;
ECHA InfoCard	100.232.884
Chemical and physical data
Formula	C13H11N3O4
Molar mass	273.248 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N;
	InChI InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18) ; Key:UVSMNLNDYGZFPF-UHFFFAOYSA-N ;
	(what is this?) (verify)

Pomalidomide, sold under the brand names Pomalyst and Imnovid, is an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma.

Pomalidomide was approved for medical use in the United States in February 2013, and in the European Union in August 2013. It is available as a generic medication.